WE Life Sciences

🌍 Why Obesity was One of the Biggest Themes in 2024, why is it important ? Obesity is becoming a key focus in 2024 for several important reasons. Health Impacts: Tackling obesity is crucial because it helps prevent a wide range of related diseases, including ☑️ Alzheimer's, ☑️ select inflammatory & immune conditions, ☑️ sleep apnea, pre-diabetes, heart failure, ☑️ obesity-associated cancers, NASH, and kidney diseases.   Workforce Impact: Addressing obesity also has a direct impact on businesses. ☑️ By reducing obesity-related health issues, Companies can keep employees healthier, improving retention rates. National Economic Benefits: It’s changing countries, ☑️ 50% of GDP growth in Denmark, is driven by one active ingredient, Novo Nordisk. ☑️ In the second quarter of 2024, Novo Nordisk's market capitalization exceeded the country's projected GDP for the year 2024 ☑️ The company who holds Novo, the Novo foundation, is now the world's largest charity foundation. Food Industry Transformation: Analysts are calling it the "snack apocalypse." ☑️ This year alone, processed food consumption is expected to drop by $6B, likely due to the impact of GLP-1s. ➡️ Obesity is no longer just a public health issue: it has become an economic driver, a strategic priority for businesses, and a catalyst for industrial transformation.   Source : Atlas Venture 2024 year in Review To contact our team for your financial needs in Life Sciences (see in the comments) 👇 https://lnkd.in/e7FacTD5 #lifesciences #pharma #health #obesisty Gery Lefebvre

✨ A major milestone for EsoBiotec and Pregenen Biopharma! The first patient has been treated with ESO-T01, the first in vivo BCMA CAR-T therapy ever administered in humans. Developed for relapsed/refractory multiple myeloma, this groundbreaking approach reprograms T lymphocytes directly inside the body, paving the way for faster and more accessible treatments. 🔍 Promising results observed after just 28 days: ✅ Cancer cells undetectable in the bone marrow ✅ Normalization of free light chain levels ✅ No significant adverse events reported As proud supporters of this type of groundbreaking technology, we believe ESO-T01 has the potential to redefine access to cell therapies for patients with hematologic malignancies. ➡️ Learn more: https://lnkd.in/eJnw_hwN ➡️ to contact our team (see link in the comments) #innovation #biotech #Myeloma Gery Lefebvre

📊 RFK Jr.'s HHS Nomination : What Does It Mean for Life Sciences ?" Since the announcement of Robert F. Kennedy Jr. as HHS Secretary, the value of life sciences subsectors has shifted significantly, adjusted against the sector average (+2.4%): 📈 Sectors that gained : ⬆️ Consumer Health ⬆️ Generic pharma ⬆️ Big pharma ⬆️ Distributors, biosimilars (+30% for Coherus BioSciences), and managed care 📉 Sectors that declined : ⬇️ Biotech ⬇️ Service providers ⬇️ CROs ⬇️ HCIT Notably, big pharmas focused on obesity (Lilly, Novo) dropped 3.3% relative to the average striking move. These changes highlight uncertainty surrounding future policies. To contact our team for your financial needs in Life Sciences (see in the comments) 👇 #lifesciences #pharma #health Gery Lefebvre

✨ The entire WE Life Sciences team wishes you all the best for 2025! 💫 For 2025, our ambition is to continue to support the rich biotech ecosystem in Wallonia. We will continue to put all our energy into projects with high added (human) value. 🚀 Thank you to those who have placed their trust in us, and welcome to those with aspirations and projects in Life Sciences! 🧪 🔬 Happy festive season! 💫   #lifesciences #biotech #medtech #health Gery Lefebvre

📢 Promising Results from PDCline Pharma’s Phase I/II Trial of PDClung01 in Stage IV NSCLC Patients PDCline Pharma presented encouraging data at ESMO-IO from its clinical trial evaluating the cancer vaccine **PDClung01** in combination with pembrolizumab for untreated stage IV NSCLC patients with high PD-L1 expression. Key Highlights: ✔️ Mild Safety Profile: PDC*lung01 showed a manageable safety profile, with most related adverse events being mild (grades 1-2). Only 2% of events led to treatment discontinuation, compared to 9.1% for pembrolizumab alone (KEYNOTE-042). ✔️ Robust Immune Response: 56% of patients exhibited tumor antigen-specific CD8+ T-cell responses, with significant correlations observed between these immune responses and improved progression-free survival (PFS). ✔️ Promising Efficacy: · Objective Response Rate (ORR): 55% (vs 39% for pembrolizumab alone in KEYNOTE-042) · Median PFS: 8.9 months (+36% improvement over KEYNOTE-042) · Disease Control Rate (DCR) : 76% Next Steps : Based on these encouraging results, PDC*line Pharma is preparing a randomized Phase IIb trial, set to begin in 2026, to further validate these findings. 👉 https://lnkd.in/e86fGxKc

🚀 Exciting Milestone for EsoBiotec: Launch of Investigator-Initiated Clinical Trial (IIT) in China 🇨🇳   EsoBiotec, a pioneering biotech company focused on empowering cells in vivo to combat cancer, has announced the launch of an Investigator-Initiated Clinical Trial (IIT) in China for ESO-T01, an in vivo BCMA CAR-T therapy for multiple myeloma.   ESO-T01, developed using their ENaBL platform, is the first in vivo BCMA CAR-T candidate to enter clinical trials. This novel approach reprograms T cells directly inside the body, offering a promising alternative to existing therapies with fewer side effects and increased accessibility.   Initial clinical data from this study are expected by mid-2025, with the potential for ESO-T01 to expand into other diseases, including autoimmune disorders.   💡 Supporting EsoBiotec: In a challenging funding landscape, EsoBiotec has raised €22M, with key investments from Thuja Capital, UCB Ventures, Invivo Partners, Wallonie Entreprendre, Sambrinvest, and INVESTSUD. This financial backing strengthens their ability to bring groundbreaking therapies to patients worldwide.   Want to know all the story ? See the link below 👇 https://lnkd.in/eJF_Haik   Need some financial support in your Life Sciences projects? (see the link below)👇     #lifesciences #innovation #cancer Gery Lefebvre Jean-Pierre Latere Dwan'Isa

📢 What changes at the FDA under the Trump administration? ➡️ With the recent appointment of Mehmet Oz as head of the CMS and Martin Makary as Director or the FDA, the biopharmaceutical industry is wondering what the consequences might be for regulatory approval processes. Certain therapeutic areas could see their development affected by these new guidelines. 🔍 Find out which therapeutic areas are affected and why this is attracting so much attention (Data from Stifel Bank 2024 report). To contact our team for your financial needs in Life Sciences (see in the comments) 👇 #lifesciences #pharma #health Gery Lefebvre

💥 BiOkuris, a spin-off from our participating biotech KitoZyme, has just signed new commercial agreements with Germany's Apriwell and @UAE's Amdis Health Sciences Middle East. The opening of the German, Austrian, Luxembourg and United Arab Emirates markets is thus assured after the French market a few months ago in partnership with Mayoly.   🧪 🍄 All this will boost the distribution of BK100, Biokuris' first therapeutic product - made from chitosan, biopolymers derived from the cell walls of a fungus - and used to treat gastrointestinal symptoms. Initial results are excellent! Good news, then, given that gastrointestinal disorders affect around 16.6% of adults in Germany alone, with some 1.1 million people diagnosed with irritable bowel syndrome and 64.9 million episodes of acute gastrointestinal illness occurring every year. And in the Arab Emirates, between two and three million patients are likely to be treated with this product.   👏 Congratulations to François Blondel's teams on this new milestone!   To find out more about Biokuris, read the L'Echo article (link in commentary to this post) 👇 And to contact our team for financial needs in Life Sciences (link in comment of this post) 👇   #lifesciences Gery Lefebvre

🚀 WE Life Sciences is thrilled to join to the €93M fundraising announced by PANTERA in September with an additional contribution of €2.6M.     With in total €95.6M , PanTera raised the Belgium's Largest Life Sciences Series A Round Ever!   🇧🇪 PanTera, a Belgian joint venture between our local heroes IBA (Louvain-la-Neuve) and SCK CEN (Mol), is on a mission to tackle the global shortage of Actinium-225 (²²⁵Ac) - a critical isotope for Targeted Alpha Therapy, an innovative cancer treatment. 🇧🇪   Leveraging SCK CEN's unique stock of pure ²²⁶ Ra and IBA’s Rhodotron® electron accelerator, PanTera will become a world-leading, reliable supplier of this life-saving medical radioisotope.   Today, WE Life Sciences announced its participation in PanTera increasing the Series A to € 95.6M, alongside EQT Group, Kurma Partners, Eurazeo, Korys, Paladin Capital Group, and our counterpart in Flanders, PMV. This record-breaking funding round will enable PanTera to produce over 100 Curies of clinical-grade ²²⁵Ac annually by 2029, benefiting over 100,000 patients per year.   💡 As the radiopharmaceutical sector continues its rapid growth, WE Life Sciences is proud to support groundbreaking innovations like PanTera’s that promise to reshape cancer treatment worldwide.   This achievement highlights Belgium's growing influence in medical innovation and its commitment to advancing life-changing therapies. 🏆 Last night, PanTera proudly received the prestigious Best Venture Capital Deal – Life Sciences 2024 award at the A&M Awards, celebrating the tremendous success of this Series A round ! Read all the story in L'Echo (see link in the comments)👇 #lifesciences #pharma Gery Lefebvre

🎉 A major milestone for innovation in cell therapy   Cellistic has just announced a significant achievement: its facility dedicated to allogeneic iPSC (induced pluripotent stem cell)-based therapies has received GMP certification from the Belgian Federal Agency for Medicines and Health Products (FAMHP), in line with EMA standards.   👉 Why is this important? This one-of-a-kind facility integrates cutting-edge technologies, including: ✅ Segregated areas for open and closed cell manufacturing ✅ Cryopreservation and packaging capabilities ✅ Bioreactor-based processes to optimize manufacturing and reduce production costs   With nearly 15 years of GMP manufacturing experience and over 400 cell therapy batches produced, Cellistic is demonstrating its expertise in safe, scalable, and innovative off-the-shelf cell therapy production. This achievement marks a major step forward for the industry and confirms Cellistic’s ability to meet the most stringent standards for allogeneic cell therapy manufacturing.   👏 Congratulations to the entire Cellistic team on this remarkable accomplishment!   👉 Read all the details in their press release (see in the comments)   👉 To contact our teams for your life sciences' financial needs (see the link in the comments) #lifesciences #therapy #health Gery Lefebvre